A couple of my initial blog posts (1, 2) focused on CMS regulation of Part D covered controlled substance prescriptions and requirements to have appropriate DEA registration.  Well, the DEA is jumping into the fray via some lucrative settlements resulting from investigations regarding similar regulations. A quick glance at the DEA news wire shows some interesting stories about their recent successes.

While I empathize with the pharmacy industry constituents and the difficulty in maintaining 100% compliance, the potential penalties underscore the need for pharmacy transaction stakeholders to uphold rigorous standards. It is imperative these stakeholders use a source of accurate prescriber DEA assignation (linked to the NPI, etc) so the appropriate validity checks can be made:

• Valid DEA Number
• Unexpired DEA Registration
• Appropriate DEA Schedule

I think we have yet to see this story play out in full as the DEA begins to find their footing with investigative practices.  We will continue to monitor and report back here as this progresses. Stay tuned.